X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
larotrectinib (21) 21
index medicus (10) 10
etv6-ntrk3 gene fusion (8) 8
oncology (8) 8
tumors (7) 7
cancer (5) 5
tropomyosin (5) 5
expression (4) 4
infantile fibrosarcoma (4) 4
ntrk (4) 4
ntrk fusion (4) 4
carcinoma (3) 3
entrectinib (3) 3
fibrosarcoma (3) 3
fusion (3) 3
humans (3) 3
metastases (3) 3
metastasis (3) 3
pan-trk (3) 3
pathology (3) 3
patient (3) 3
pediatrics (3) 3
pembrolizumab (3) 3
precision medicine (3) 3
sarcoma (3) 3
targeted therapy (3) 3
trk inhibitor (3) 3
abridged index medicus (2) 2
afatinib (2) 2
aggressive behavior (2) 2
animals (2) 2
biochemical research methods (2) 2
breast cancer (2) 2
chemistry, analytical (2) 2
chemotherapy (2) 2
children (2) 2
congenital mesoblastic nephroma (2) 2
dslim-2006 (2) 2
etv6-ntrk3 (2) 2
genes (2) 2
hematology (2) 2
hybridization (2) 2
kinase (2) 2
kinases (2) 2
leukemia (2) 2
loxo-101 (2) 2
malignant peripheral nerve sheath tumor (2) 2
mice (2) 2
modufolin (2) 2
muscle proteins (2) 2
myl-1401o (2) 2
neurotrophic receptor tyrosine kinase (2) 2
oncogene (2) 2
original (2) 2
original article (2) 2
pediatric (2) 2
personalized medicine (2) 2
pharmacology & pharmacy (2) 2
protein kinase inhibitors - chemistry (2) 2
protein-tyrosine kinase (2) 2
rearrangement (2) 2
receptor, trka - antagonists & inhibitors (2) 2
receptor, trka - genetics (2) 2
review (2) 2
secretory breast carcinoma (2) 2
signal transduction (2) 2
subset (2) 2
surgery (2) 2
trk (2) 2
trk fusion cancer (2) 2
tyrosine (2) 2
1506 (1) 1
abl (1) 1
acquired-resistance (1) 1
activating kinase (1) 1
acute lymphoblastic leukemia (1) 1
acute lymphoblastic-leukemia (1) 1
adult (1) 1
algorithms (1) 1
alk (1) 1
all (1) 1
analysis (1) 1
article (1) 1
aspiration biopsy (1) 1
b-progenitor (1) 1
basal-like carcinoma (1) 1
basal‐like carcinoma (1) 1
bcr-abl1-like all (1) 1
best practice (1) 1
biochemistry & molecular biology (1) 1
biopsy (1) 1
biotechnology & applied microbiology (1) 1
bone (1) 1
bone metastasis (1) 1
bone remodelling (1) 1
breast (1) 1
breast carcinoma (1) 1
breast-cancer (1) 1
cancer genomics (1) 1
cancer screening (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Pharmacogenomics, 08/2019, Volume 20, Issue 13, p. 927
Journal Article
Recent Results in Cancer Research, ISSN 0080-0015, 2018, Volume 211, pp. 141 - 151
One of the most challenging issues in oncology research and treatment is identifying oncogenic drivers within an individual patient's tumor which can be... 
LOXO-101 | Larotrectinib | NTRK genes | TRK receptor family
Journal Article
Annals of Oncology, ISSN 0923-7534, 02/2019, Volume 30, Issue 2, pp. 325 - 331
Abstract Background NTRK1, NTRK2 and NTRK3 gene fusions (NTRK gene fusions) occur in a range of adult cancers. Larotrectinib is a potent and highly selective... 
Adult | Trk fusion cancer | Larotrectinib | Phase i | Ntrk gene fusion | larotrectinib | NTRK gene fusion | ONCOLOGY | ETV6-NTRK3 GENE FUSION | phase I | adult | TRK fusion cancer | NTRK FUSION | Original
Journal Article
Pathology - Research and Practice, ISSN 0344-0338, 09/2019, p. 152662
Journal Article
The American Journal of Surgical Pathology, ISSN 0147-5185, 04/2019, Volume 43, Issue 4, pp. 435 - 445
Pediatric mesenchymal tumors harboring variant NTRK fusions (ETV6-negative) are being increasingly described; however, the histologic and clinical features of... 
NTRK | soft tissue sarcoma | TRK | infantile fibrosarcoma | pediatric | ALK | SURGERY | LAROTRECTINIB | PAN-TRK | MANAGEMENT | TISSUE | CONGENITAL MESOBLASTIC NEPHROMA | PATHOLOGY | SUBSET | CHILDREN | ETV6-NTRK3 GENE FUSION | Tumors in children | Development and progression | Genetic aspects | Sarcoma | Health aspects | Gene fusion
Journal Article
Gynecologic Oncology Reports, ISSN 2352-5789, 05/2019, Volume 28, pp. 141 - 144
•<1% of cervical cancers are sarcomas.•Data on neurofibrosarcoma management is scarce.•Larotrectinib is approved for NTRK1 gene fusion tumors without acquired... 
Larotrectinib | NTRK-1 | Neurofibrosarcoma | Targeted therapy | Cervical cancer | Malignant peripheral nerve sheath tumor
Journal Article
Pediatric Blood & Cancer, ISSN 1545-5009, 10/2018, Volume 65, Issue 10, pp. e27271 - n/a
Mesoblastic nephroma is the most frequent renal tumor in newborns and young infants, and the cellular type is characterized by an ETV6–NTRK fusion, which... 
ETV6–NTRK | mesoplastic nephroma | larotrectinib | bone metastasis | TRK inhibitor | ONCOLOGY | INFANTILE FIBROSARCOMA | RECURRENT | ETV6-NTRK3 GENE FUSION | PEDIATRICS | ETV6-NTRK | HEMATOLOGY | INFANCY | Genetic disorders | Metastasis | Neonates | Signal transduction | Bone remodelling | Tropomyosin | Infants | Bone | Metastases
Journal Article
Expert Review of Anticancer Therapy, ISSN 1473-7140, 01/2019, Volume 19, Issue 1, pp. 1 - 10
Introduction: TRK fusions occur across a wide range of cancers in children and adults. These fusions drive constitutive expression and ligand-independent... 
Larotrectinib | NTRK | TRK inhibitor | TRK fusion | neurotrophin receptor | INFANTILE FIBROSARCOMA | CONGENITAL MESOBLASTIC NEPHROMA | PROTEIN-TYROSINE KINASE | TROPOMYOSIN | CANCER | RECEPTOR KINASE | ONCOLOGY | ETV6-NTRK3 GENE FUSION | THYROID-CARCINOMA | PATIENT | NTRK FUSION
Journal Article
ONCOTARGETS AND THERAPY, ISSN 1178-6930, 2019, Volume 12, pp. 3171 - 3179
The development of deep-sequencing methods is now unveiling a new landscape of previously undetected gene fusion across different tumor types. Chromosomal... 
RET | TRANSFORMATION | larotrectinib | PAN-TRK | ETV6-NTRK3 | INHIBITOR ENTRECTINIB | KINASE | ACQUIRED-RESISTANCE | REARRANGEMENTS | resistance | ONCOGENE | chromosomal rearrangements | ONCOLOGY | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | NTRK | CARCINOMA | Clinical trials | FDA approval | Tumors
Journal Article
Best Practice & Research Clinical Haematology, ISSN 1521-6926, 12/2018, Volume 31, Issue 4, pp. 351 - 356
Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL), or -like ALL, is a high-risk subtype of B-cell precursor ALL characterized by a gene... 
ALL | Dasatinib | Ruxolitinib | Larotrectinib | Acute lymphoblastic leukemia | JAK-STAT | BCR-ABL1-like ALL | Ph-like ALL | ABL | Philadelphia chromosome-like ALL | St Jude TXVII | KINASE INHIBITOR THERAPY | PERSISTENCE | REARRANGEMENT | GENOMIC LANDSCAPE | ACTIVATING KINASE | ACUTE LYMPHOBLASTIC-LEUKEMIA | ETV6-NTRK3 GENE FUSION | HEMATOLOGY | EXPRESSION | B-PROGENITOR | CRLF2 | Chemotherapy | Gene expression | Leukemia | Cancer
Journal Article
Journal Article
Current Oncology Reports, ISSN 1523-3790, 2/2019, Volume 21, Issue 2, pp. 1 - 5
In this review, we highlight the pre-clinical development, recent clinical studies, and future directions of larotrectinib in patients with NTRK... 
Larotrectinib | Medicine & Public Health | Precision medicine | TRK inhibitor | Oncology | NTRK | Targeted oncology | Personalized medicine | RECEPTOR | KINASE INHIBITOR | ENTRECTINIB | ONCOLOGY | ETV6-NTRK3 GENE FUSION | GROWTH | PATIENT | EXPRESSION | NTRK FUSION | Tyrosine | Medicine, Experimental | Medical research | Pharmacogenetics | Muscle proteins
Journal Article
Drugs of the Future, ISSN 0377-8282, 2017, Volume 42, Issue 2, pp. 131 - 133
Journal Article
DRUGS OF THE FUTURE, ISSN 0377-8282, 05/2017, Volume 42, Issue 5, pp. 275 - 280
Larotrectinib (LOXO-101) is a small-molecule ATP-competitive oral inhibitor of the tropomyosin-related kinase (Trk) family of receptor kinases, including... 
LOXO-101 | Larotrectinib | FUSION | Tropomyosin-related kinase (Trk) inhibitor | PHARMACOLOGY & PHARMACY | KINASE INHIBITOR LOXO-101 | CANCER
Journal Article
DRUGS OF THE FUTURE, ISSN 0377-8282, 02/2017, Volume 42, Issue 2, pp. 131 - 133
The European Cancer Organisation's 2017 European Cancer Congress (ECCO2017), held in Amsterdam, the Netherlands, brought together a wide range of attendees... 
Pembrolizumab | Afatinib | Myl-1401O | dSLIM-2006 | PHARMACOLOGY & PHARMACY | Modufolin | Larotrectinib Niraparib | Lenvatinib Trastuzumab
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.